This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Collagen Cross-linking in Infectious Keratitis Trial

This study has been completed.
Information provided by (Responsible Party):
Ngamjit Kasetsuwan, Chulalongkorn University Identifier:
First received: April 6, 2013
Last updated: May 1, 2015
Last verified: April 2013
The purpose of this study is to evaluate the efficacy of collagen cross-linking for treatment of infectious keratitis.

Condition Intervention Phase
Infectious Keratitis Bacterial Keratitis Fungal Keratitis Procedure: Collagen cross-linking Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Collagen Cross-linking in Infectious Keratitis Trial

Resource links provided by NLM:

Further study details as provided by Ngamjit Kasetsuwan, Chulalongkorn University:

Primary Outcome Measures:
  • decrement of infiltration size [ Time Frame: 1 months ]
    decrement of infiltration size between day0 and day 30

Secondary Outcome Measures:
  • number of participants with adverse events [ Time Frame: 1 months ]
    adverse events after corneal collagen cross-linking (report in descriptive study)

Enrollment: 30
Study Start Date: March 2013
Study Completion Date: December 2014
Primary Completion Date: March 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Collagen cross-linking
Collagen cross-linking with standard treatment
Procedure: Collagen cross-linking

Collagen cross-linking arm will receive standard medication for corneal ulcer treatment and corneal collagen cross-linking.

Standard treatment arm will receive only standard medication.

No Intervention: standard treatment
Standard treatment alone


Ages Eligible for Study:   6 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Evidence of corneal ulcer grade II or III (bacteria or fungal, or presumed bacterial or fungal)
  • Age more than 6 year
  • Patients can understand and can follow the study protocol

Exclusion Criteria:

  • Pregnancy by history or urine test
  • Evidence of herpetic keratitis
  • Evidence of corneal perforation
  • Evidence of autoimmune disease
  • Known allergy to study medication
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01831206

Ophthalmology department, King Chulalongkorn Memorial hospital
Pratumwan, Bangkok, Thailand, 10330
Sponsors and Collaborators
Chulalongkorn University
  More Information

Responsible Party: Ngamjit Kasetsuwan, Associated professor, Chulalongkorn University Identifier: NCT01831206     History of Changes
Other Study ID Numbers: 438/55
Study First Received: April 6, 2013
Last Updated: May 1, 2015

Keywords provided by Ngamjit Kasetsuwan, Chulalongkorn University:
corneal ulcer

Additional relevant MeSH terms:
Communicable Diseases
Corneal Diseases
Eye Diseases processed this record on September 21, 2017